Erythropoietin

Research output: Contribution to journalArticle

Abstract

Erythropoietin is a glycoprotein hormone produced in the kidneys and to a lesser extent in the liver which regulates the proliferation and differentiation of erythroid progenitor cells. The gene for erythropoietin is well conserved and the hormone is always present in the plasma even in the renoprival state, emphasizing its important physiologic role. Failure to produce adequate quantities of erythropoietin leads to severe anemia, a situation most often encountered in patients with end stage renal disease. With the application of recombinant DNA technology, the gene for erythropoietin has been molecularly cloned, sequenced and expressed in a biologically active form in mammalian cells. In recent clinical trials, the recombinant hormone has been demonstrated to correct anemia in patients with severe end stage renal disease and alleviate their transfusion requirements.

Original languageEnglish (US)
Pages (from-to)130-135
Number of pages6
JournalBlood Reviews
Volume3
Issue number2
DOIs
StatePublished - 1989

Fingerprint

Erythropoietin
Hormones
Chronic Kidney Failure
Anemia
Erythroid Precursor Cells
Recombinant DNA
Genes
Glycoproteins
Clinical Trials
Technology
Kidney
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Erythropoietin. / Spivak, Jerry L.

In: Blood Reviews, Vol. 3, No. 2, 1989, p. 130-135.

Research output: Contribution to journalArticle

Spivak, Jerry L. / Erythropoietin. In: Blood Reviews. 1989 ; Vol. 3, No. 2. pp. 130-135.
@article{10b3e2bff9134369b46e41a2026a8e2e,
title = "Erythropoietin",
abstract = "Erythropoietin is a glycoprotein hormone produced in the kidneys and to a lesser extent in the liver which regulates the proliferation and differentiation of erythroid progenitor cells. The gene for erythropoietin is well conserved and the hormone is always present in the plasma even in the renoprival state, emphasizing its important physiologic role. Failure to produce adequate quantities of erythropoietin leads to severe anemia, a situation most often encountered in patients with end stage renal disease. With the application of recombinant DNA technology, the gene for erythropoietin has been molecularly cloned, sequenced and expressed in a biologically active form in mammalian cells. In recent clinical trials, the recombinant hormone has been demonstrated to correct anemia in patients with severe end stage renal disease and alleviate their transfusion requirements.",
author = "Spivak, {Jerry L}",
year = "1989",
doi = "10.1016/0268-960X(89)90008-8",
language = "English (US)",
volume = "3",
pages = "130--135",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Erythropoietin

AU - Spivak, Jerry L

PY - 1989

Y1 - 1989

N2 - Erythropoietin is a glycoprotein hormone produced in the kidneys and to a lesser extent in the liver which regulates the proliferation and differentiation of erythroid progenitor cells. The gene for erythropoietin is well conserved and the hormone is always present in the plasma even in the renoprival state, emphasizing its important physiologic role. Failure to produce adequate quantities of erythropoietin leads to severe anemia, a situation most often encountered in patients with end stage renal disease. With the application of recombinant DNA technology, the gene for erythropoietin has been molecularly cloned, sequenced and expressed in a biologically active form in mammalian cells. In recent clinical trials, the recombinant hormone has been demonstrated to correct anemia in patients with severe end stage renal disease and alleviate their transfusion requirements.

AB - Erythropoietin is a glycoprotein hormone produced in the kidneys and to a lesser extent in the liver which regulates the proliferation and differentiation of erythroid progenitor cells. The gene for erythropoietin is well conserved and the hormone is always present in the plasma even in the renoprival state, emphasizing its important physiologic role. Failure to produce adequate quantities of erythropoietin leads to severe anemia, a situation most often encountered in patients with end stage renal disease. With the application of recombinant DNA technology, the gene for erythropoietin has been molecularly cloned, sequenced and expressed in a biologically active form in mammalian cells. In recent clinical trials, the recombinant hormone has been demonstrated to correct anemia in patients with severe end stage renal disease and alleviate their transfusion requirements.

UR - http://www.scopus.com/inward/record.url?scp=0024401872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024401872&partnerID=8YFLogxK

U2 - 10.1016/0268-960X(89)90008-8

DO - 10.1016/0268-960X(89)90008-8

M3 - Article

C2 - 2673445

AN - SCOPUS:0024401872

VL - 3

SP - 130

EP - 135

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 2

ER -